军事知识服务平台
我国研究者发起的临床研究药品管理问题及对策分析
Problems and countermeasures of the drug management in investigator-initiated trials of China
摘要 研究者发起的临床研究(investigator-initiated trials,IIT)的药品质量和用药安全对保障受试者权益及研究数据的可靠性至关重要。作者通过梳理国外IIT药品管理模式,探讨了我国IIT药品管理现状以及存在的主要问题,包括国家层面缺少针对IIT药品的专项管理规范,医疗卫生机构内部IIT药品管理流程有待完善,药品质量与合规性存在风险,管理资源投入不足以及药学监管及溯源困难。在此基础上,进一步结合国内外先进经验与我国实际情况,提出以下对策:制定配套的药品管理规范,强化药品管理的前置审批与科学性/伦理/合同审查,建立统一管理制度与标准操作规程以及推进信息化建设等,以期提升IIT药品管理效率与质量,保障试验用药安全,为我国IIT的规范化可持续发展提供管理支撑。
Abstract:
The quality and safety of drugs used in investigator-initiated trials (IIT) are crucial to safeguarding the rights of trial participants and ensuring the reliability of research data. Through analyzing international IIT drug management modes, the author examined the current state of IIT drug management in China, and identified the main challenges, including the lack of specific regulatory standards for IIT drugs at the national level, the need to improve internal IIT drug management processes in healthcare institutions, risks related to drug quality and compliance, insufficient allocation of management resources, and difficulties in pharmaceutical oversight and traceability. Based on this, and drawing on advanced domestic and international practices while taking into account China′s actual conditions, the following measures were proposed: formulating supporting drug management regulations, strengthening prior approval and scientific / ethical / contracts review of drug, establishing a unified management system and standard operating procedures, and advancing the development of information systems. These measures aimed to enhance the efficiency and quality of drug management in IIT, ensure the safety of trial drugs, as well as provide managerial supports for the standardized and sustainable development of IIT in China.